AndrasHeczeyMD
Pediatric Hematology & Oncology • Houston, TXAssociate professor, Pediatric Hematology & Oncology, Baylor College of Medicine
Dr. Heczey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1102 Bates Ave
Houston, TX 77030Phone+1 832-824-1000- Is this information wrong?
Summary
- Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target several solid tumors (including hepatoblastoma, hepatocellular carcinoma, yolk sac tumors, Wilms tumor, rhabdoid tumors etc) when expressed in T cells.
As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target glypican-3 (GPC3) with genetically-engineered T lymphocytes. His team is currently evaluating Interleukin-15 and GPC3-CAR expressing T cells in children with solid tumors.
His ultimate goal is to cure all patients with solid cancers by effectively translating preclinical findings from bench-to-bedside.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2009 - 2012
Children's Hospital Los AngelesResidency, Pediatrics, 2006 - 2009
Semmelweis UniversityClass of 2002
Certifications & Licensure
CA State Medical License 2009 - 2025
TX State Medical License 2010 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) Start of enrollment: 2019 Mar 28
- GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma Start of enrollment: 2018 Jan 18
- T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) Start of enrollment: 2020 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.Andres F Espinoza, Roma H Patel, Kalyani R Patel, Andrew A Badachhape, Richard Whitlock, Rohit K Srivastava, Saiabhiroop R Govindu, Ashley Duong, Abhishek Kona, Pavan ...> ;Journal of Hepatology. 2024 Apr 1
- Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.Andras Heczey, Xin Xu, Amy N Courtney, Gengwen Tian, Gabriel A Barragan, Linjie Guo, Claudia Martinez Amador, Nisha Ghatwai, Purva Rathi, Michael S Wood, Yanchuan Li, ...> ;Nature Medicine. 2024 Apr 1
- GD2-CAR CAR T cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter.Arnett, A., Heczey, A.> ;Cancer Cell. 2024 Jan 8
- Join now to see all
Press Mentions
- Promising Results for CAR-NKT Cell Therapy Against Neuroblastoma in Phase 1 TrialMay 16th, 2023
- CAR-NKT Cell Therapy Shows Promising Results Against Neuroblastoma in Phase 1 Clinical TrialMay 15th, 2023
- Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual MeetingMay 17th, 2021
- Join now to see all
Hospital Affiliations
Texas Children's HospitalHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
